Litigation Details for ALLERGAN, INC. v. APOTEX INC. (M.D.N.C. 2012)

ALLERGAN, INC. v. APOTEX INC. (M.D.N.C. 2012)

Docket		Date Filed	2012-03-13
Court	District Court, M.D. North Carolina	Date Terminated	2015-01-20
Cause	35:271 Patent Infringement	Assigned To	Catherine Caldwell Eagles
Jury Demand	Both	Referred To	Lawrence Patrick Auld
Parties	HI-TECH PHARMACAL CO., INC.
Patents	6,403,649; 7,351,404; 7,388,029; 8,038,988; 8,101,161; 8,263,054
Attorneys	JEFFREY DEAN PATTON
Firms	Teague Rotenstreich Stanaland Fox & Holt, Pllc
Link to Docket	External link to docket

Details for ALLERGAN, INC. v. APOTEX INC. (M.D.N.C. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-03-13				External link to document

Allergan v. Apotex, 1:12-cv-00247: Litigation Summary and Patent Analysis

Last updated: August 31, 2026

Allergan, Inc. v. Apotex Inc., No. 1:12-cv-00247, was a Hatch-Waxman patent case involving Combigan, Allergan’s fixed-dose ophthalmic solution containing brimonidine and timolol. The case concerned U.S. Patent No. 7,642,258, which claimed a specific combination of the two glaucoma drugs with the preservative system Purite. The District of Delaware held the asserted claims valid and infringed based on Apotex’s abbreviated new drug application, or ANDA. The Federal Circuit affirmed. The decision preserved Allergan’s patent protection for the claimed Combigan formulation until the patent’s expiration, subject to any applicable regulatory exclusivity and later commercial arrangements. [1], [2]

What drug and patent were involved in Allergan v. Apotex?

The litigation involved Combigan ophthalmic solution, an Allergan product indicated for lowering elevated intraocular pressure in patients with glaucoma or ocular hypertension.

Item	Details
Brand drug	Combigan
Active ingredients	Brimonidine tartrate and timolol maleate
Dosage form	Ophthalmic solution
Therapeutic category	Glaucoma and ocular-hypertension treatment
NDA holder	Allergan, Inc.
Asserted patent	U.S. Patent No. 7,642,258
Patent title	Ophthalmic compositions containing brimonidine and timolol
District Court	U.S. District Court for the District of Delaware
Civil action	No. 1:12-cv-00247
District judge	Gregory M. Sleet
Federal Circuit decision	754 F.3d 952 (Fed. Cir. 2014)

The asserted patent covered a formulation combining brimonidine and timolol in a particular ophthalmic composition. The formulation also used Purite, a stabilized oxychloro complex used as a preservative. The patent claims were directed to the combination and formulation characteristics rather than to brimonidine or timolol as standalone active ingredients. [1]

What triggered the patent litigation?

Apotex filed an ANDA seeking FDA approval to market a generic version of Combigan. Its ANDA included a Paragraph IV certification asserting that the ’258 patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

Allergan responded by filing suit under the Hatch-Waxman Act. The lawsuit triggered the statutory 30-month stay of FDA approval applicable to a timely patent infringement action based on a Paragraph IV certification. The central dispute was whether Apotex’s proposed ophthalmic formulation fell within the scope of the asserted claims and whether those claims were invalid as obvious in view of the prior art. [1]

What was Apotex’s Paragraph IV position?

Apotex challenged the ’258 patent on invalidity and noninfringement grounds. The principal invalidity issue was obviousness under 35 U.S.C. § 103.

Apotex argued that persons skilled in the art would have had reason to combine brimonidine and timolol in an ophthalmic composition. Both active ingredients were known glaucoma therapies, and the prior art disclosed their use in ophthalmic treatment. Apotex also relied on prior art concerning preservatives and ophthalmic formulations.

Allergan argued that the claimed formulation was not an ordinary or predictable combination. The company relied on the claimed use of Purite, the specific composition, and evidence that the formulation achieved acceptable stability and commercial performance.

What did the District of Delaware decide?

The District of Delaware ruled for Allergan after a bench trial. The court concluded that Apotex’s ANDA product would infringe the asserted claims of the ’258 patent and that Apotex had not established invalidity by clear and convincing evidence. [1]

How did the court analyze obviousness?

The court applied the conventional obviousness framework under Graham v. John Deere Co. and considered:

1. The scope and content of the prior art.
2. Differences between the prior art and the asserted claims.
3. The level of ordinary skill in the art.
4. Objective indicia of nonobviousness.

The court rejected Apotex’s argument that the claimed formulation was merely the predictable combination of known glaucoma ingredients. The prior art did not sufficiently establish that a skilled artisan would have selected the claimed formulation, including the Purite-based preservative system, with a reasonable expectation of success.

The court also considered secondary considerations, including commercial success, industry acceptance, and the relationship between the claimed features and Combigan’s market performance. Those factors supported the nonobviousness determination, although the court’s ruling rested on the full evidentiary record rather than commercial success alone. [1]

What infringement ruling did the court issue?

The infringement analysis focused on the composition of Apotex’s proposed generic product as described in its ANDA. Under Hatch-Waxman law, the relevant question was whether making, using, or selling the product described in the ANDA would infringe the patent.

The court determined that Apotex’s proposed product met the limitations of the asserted claims. Allergan therefore established infringement based on the ANDA filing.

What did the Federal Circuit decide?

The Federal Circuit affirmed the District of Delaware’s judgment in 2014. The appellate court upheld the conclusion that the asserted claims of the ’258 patent were not shown to be obvious. [2]

The Federal Circuit’s analysis addressed whether the prior art provided an adequate reason to combine the relevant components and whether it supplied a reasonable expectation that the resulting formulation would work as claimed. The court agreed that Apotex had not carried its burden.

The decision is important because it rejected a broad “known components, predictable combination” theory in the context of a pharmaceutical formulation patent. The presence of known active ingredients did not, by itself, establish obviousness where the claimed formulation involved additional technical limitations and the prior art did not adequately support the proposed combination.

What was the final litigation result?

Issue	Result
ANDA-based infringement	Allergan prevailed
Validity	Asserted claims upheld against Apotex’s obviousness challenge
District Court judgment	For Allergan
Federal Circuit appeal	Affirmed
Paragraph IV challenge	Unsuccessful
Generic approval under the challenged ANDA	Delayed by the patent litigation and statutory stay
Controlling appellate authority	Allergan, Inc. v. Apotex Inc., 754 F.3d 952 (Fed. Cir. 2014)

When did the Combigan patent lose exclusivity?

The ’258 patent had an expected expiration in 2022, subject to the patent-term calculation recorded by the USPTO and FDA. Public patent records identify the patent’s expiration date as May 19, 2022. [3], [4]

Exclusivity category	Relevant date or status
Patent	U.S. Patent No. 7,642,258
Patent expiration	May 19, 2022, according to public patent records
Regulatory exclusivity	Separate from patent protection and dependent on FDA records
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA under Hatch-Waxman

Patent expiration does not automatically establish the first commercial generic launch date. Launch timing can depend on FDA approval, other listed patents, pediatric exclusivity, settlements, supply arrangements, and business decisions by the ANDA sponsor.

What was the Orange Book status of Combigan?

Combigan was approved through FDA NDA No. 021398. Orange Book-listed patents are the principal patents relevant to an ANDA Paragraph IV dispute. The ’258 patent was listed for Combigan and formed the basis of the Allergan-Apotex case. [4]

The case illustrates the commercial value of a formulation patent. Brimonidine and timolol were established active ingredients, but the asserted patent protected the fixed-dose ophthalmic combination and formulation architecture. A generic sponsor could not avoid the patent merely by relying on the fact that each active ingredient was individually known.

The Orange Book status must be evaluated by product and historical date. Listings can change through patent expiration, delisting, patent-term adjustments, pediatric extensions, or FDA administrative updates.

What formulations were protected by U.S. Patent No. 7,642,258?

The ’258 patent protected claims directed to an ophthalmic composition containing brimonidine, timolol, and the claimed preservative and formulation limitations.

The commercial significance of the patent arose from the fixed-dose product format. Combigan combines two established glaucoma therapies in one ophthalmic product, reducing administration burden relative to separate products. The patent did not create broad exclusivity over all brimonidine or timolol products. Its value depended on the scope of the issued claims and whether a proposed generic formulation satisfied each limitation.

Why was Purite significant?

Purite was significant because the asserted formulation claims included limitations concerning the preservative system. Allergan relied on the technical characteristics of the claimed formulation to distinguish Combigan from earlier compositions and to rebut Apotex’s obviousness case.

The litigation therefore involved more than a simple comparison of active ingredients. The preservative system, concentration ranges, and composition details affected both infringement and validity.

How strong was Allergan’s patent estate for Combigan?

The ’258 patent was commercially meaningful but relatively concentrated. Its strength came from three factors:

1. It covered the fixed-dose combination used in Combigan.
2. The Federal Circuit affirmed its validity after a full obviousness challenge.
3. The patent was listed for the branded product and could delay approval of an ANDA sponsor through Hatch-Waxman litigation.

Its limitations were equally important. The case did not establish broad protection over every brimonidine-timolol product. A noninfringing formulation could potentially avoid the patent if it did not meet all claim limitations. The patent also did not prevent competition indefinitely because its term ended in 2022.

Patent-strength factor	Assessment
Validity after appellate review	Strong against the litigated obviousness challenge
Infringement position	Strong against Apotex’s ANDA product
Breadth	Focused on the claimed combination and formulation
Remaining term at Federal Circuit decision	Several years
Design-around potential	Dependent on claim limitations and product formulation
Biosimilar relevance	None
Generic risk after expiration	High, subject to FDA approval and other barriers

Which companies challenged Combigan’s patent protection?

Apotex was the defendant and ANDA sponsor in this action. The case record does not make this action a multi-defendant proceeding. Other companies may have pursued separate Combigan-related regulatory or patent strategies, but those matters should not be treated as part of No. 1:12-cv-00247.

The litigation established that Apotex’s proposed product, as described in its ANDA, could not proceed on the basis of its invalidity and noninfringement positions.

Did Allergan and Apotex enter a settlement agreement?

The reported district court and Federal Circuit decisions resolve the litigated dispute through a judgment for Allergan and affirmance on appeal. The cited appellate decision does not identify a settlement agreement that replaced the judgment.

The absence of a settlement discussion in the controlling appellate opinion does not establish that no later commercial arrangement existed outside the reported decision. For legal analysis of this specific case, the operative public outcome is the judgment and affirmance rather than a reported settlement framework. [1], [2]

What patent litigation affected generic launch timing?

The litigation delayed FDA approval of Apotex’s ANDA through the Hatch-Waxman process. Allergan filed suit after Apotex’s Paragraph IV certification, creating the statutory 30-month stay.

The judgment did not permanently block generic competition. It preserved the patent’s exclusionary effect for the remaining patent term. After expiration, the primary barriers shifted from patent enforcement to FDA approval, manufacturing readiness, market access, pricing, and any other applicable Orange Book-listed rights.

Generic launch scenarios

Scenario	Commercial consequence
Apotex loses litigation and waits for patent expiration	Launch generally delayed until patent and regulatory barriers clear
Apotex obtains reversal or invalidity ruling	Earlier FDA approval and potential launch
Apotex designs around the claims	Potential launch if the redesigned product is noninfringing and FDA-compliant
Patent expires before approval	Patent barrier falls, but regulatory approval remains necessary
Later settlement or license	Launch date depends on agreed entry terms

Were biosimilar risks relevant to this case?

No. Combigan is a small-molecule drug product, and Apotex proceeded through the ANDA pathway. The case did not involve a biologic license application, a biosimilar application under the Biologics Price Competition and Innovation Act, or biologic interchangeability.

The relevant competitive risk was generic substitution, not biosimilar substitution.

Did the case involve licensing deals or manufacturing barriers?

The reported decisions focus on patent validity and ANDA infringement. They do not disclose a material licensing transaction or a manufacturing-process patent dispute as the basis for the judgment.

The principal IP barrier was the finished-product formulation patent. Manufacturing capability could still affect a generic launch, but the reported case does not identify a separate manufacturing patent or trade-secret issue that controlled the outcome.

What was the commercial exposure for Allergan?

Combigan was a branded ophthalmic glaucoma product, and patent protection supported Allergan’s ability to defer direct generic substitution. The case preserved that protection against Apotex for the remaining life of the ’258 patent.

A precise revenue figure should not be attributed to this case without linking sales data to the relevant reporting period and product definition. The commercial exposure was the loss of fixed-dose Combigan exclusivity to an approved generic product. That exposure would have affected price, volume, formulary position, and substitution rates after patent expiry.

Key Takeaways

• Allergan sued Apotex after a Paragraph IV challenge to the Combigan formulation patent.
• The case involved U.S. Patent No. 7,642,258 and Combigan ophthalmic solution.
• The asserted patent covered a brimonidine-timolol formulation with claim-specific preservative and composition limitations.
• The District of Delaware held the patent valid against Apotex’s obviousness challenge and infringed by Apotex’s ANDA product.
• The Federal Circuit affirmed in 2014.
• Public patent records identify May 19, 2022, as the patent expiration date.
• The dispute involved generic, not biosimilar, competition.
• The case produced a judgment for Allergan, and the cited appellate record does not report a settlement replacing that judgment.
• The patent estate was strong against the litigated Apotex product but did not broadly cover every brimonidine or timolol formulation.
• After expiration, FDA approval and commercial execution became the principal generic-entry variables.

FAQs

What is the citation for Allergan v. Apotex?

The Federal Circuit decision is Allergan, Inc. v. Apotex Inc., 754 F.3d 952 (Fed. Cir. 2014). The district court action was No. 1:12-cv-00247 in the District of Delaware.

Which glaucoma drug was protected by the patent?

The patent was associated with Combigan, a fixed-dose ophthalmic solution containing brimonidine and timolol.

What type of patent was asserted against Apotex?

Allergan asserted a formulation and composition patent, not a patent covering only brimonidine or timolol as individual molecules.

Could Apotex launch before the patent expired?

Not based on the ANDA product adjudicated in the case. Apotex lost on infringement and validity, and the patent remained an obstacle through its term unless another legal or commercial resolution applied.

Is this case relevant to Restasis or other Allergan products?

No. The case concerned Combigan and the ’258 patent. It should not be used as a direct precedent for Allergan’s separate Restasis, Botox, Lumigan, or other product-specific patent estates.

References

1. U.S. District Court for the District of Delaware. (2013). Allergan, Inc. v. Apotex Inc., No. 1:12-cv-00247, trial and final judgment materials.

2. U.S. Court of Appeals for the Federal Circuit. (2014). Allergan, Inc. v. Apotex Inc., 754 F.3d 952.

3. United States Patent and Trademark Office. (2010). U.S. Patent No. 7,642,258: Ophthalmic compositions containing brimonidine and timolol.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book, NDA No. 021398.